Scancell Share Discussion Threads

[inanaco] 19/9/2023 07:47

go all in verified

[ruckrover] 19/9/2023 07:47

I wonder if the RNS had to be brought forward because the cat was out the bag?Maybe the plan was for a bigger impact on the day of the presentation?

[inanaco] 19/9/2023 07:46

No Risk .......... verified

[ruckrover] 19/9/2023 07:45

Inan,"and Colin from accounts sold .."The latest RNS is great news for patients and shareholders alike. One of the greatest validations of the science we have had to date.And all you can do is gloat?

[plasybryn] 19/9/2023 07:45

I expect that is what Lindy fears. Her days of independence are probably numbered. I expect she is really annoyed about the leak yesterday. Not what she would of hoped for for her big day. Taken the edge of it as she gets ready to present in Milan - no doubt the star of the conference. Nevertheless this is an amazing day for Lindy & her team. Very well deserved. I hope they enjoy it.

[inanaco] 19/9/2023 07:43

Dear Kept mans diary

£8 a share is achievable

[phoenixs] 19/9/2023 07:41

It is an excellent RNS. So good to see great data.

[chillpill] 19/9/2023 07:34

Data is everything and all the signs from the early data it is better than the standard of care.

Personally I think SCLP will be taken out at a huge premium in the next 18 months.

Just look at Merck’s statement re the patent cliff for Keytruda in 2027.

[inanaco] 19/9/2023 07:28

and Colin from accounts sold ............


love it

[inanaco] 19/9/2023 07:23

blown away ............

we are Commercial Crumbs !! and that is now "Very"

£1.5 billion .... sales potential

[torquayfan] 19/9/2023 07:21

Scancell Hlds - Positive data from Phase 2 SCOPE trial with SCIB1 #SCLP @scancellpharma

#voxmarkets

[torquayfan] 19/9/2023 07:15

Analyst and investor webcast

""" Professor Lindy Durrant, Chief Executive Officer, and Sath Nirmalananthan, Chief Financial Officer, will host a live webcast and Q&A session for analysts and investors at 13:00 BST / 8:00 ET. If you would like to join the webcast, please follow this link:



Issuer Services | London Stock Exchange | SCANCELL HOLDINGS PLC (lsegissuerservices.com)



A replay of the webcast will be made available shortly afterwards."""

[dominoman] 19/9/2023 07:14

I've kept hope going on this one for a long time as it drifted down. Interesting to find out why it's suddenly coming back

[pharmaboy3] 19/9/2023 07:13

Scancell Hlds - Positive data from Phase 2 SCOPE trial with SCIB1 #SCLP @scancellpharma HTTps://www.voxmarkets.co.uk/rns/announcement/6cc48a87-be62-46eb-8ded-e8c33b178f58 #voxmarkets

[torquayfan] 19/9/2023 07:13

""" Scancell announces positive data from the first stage in its Phase 2 SCOPE trial with SCIB1 cancer vaccine delivered by needle free injection for advanced melanoma



Key Highlights



· SCOPE trial surpasses its first milestone with an 82% response rate



· To our knowledge no other combination has achieved this response rate with doublet checkpoint inhibitors in unresectable metastatic melanoma



· Analyst and Investor webcast today at 1pm, full details below



Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces positive data from the first stage in its Phase 2 SCOPE trial, investigating SCIB1 in combination with checkpoint inhibitors (CPIs) in advanced melanoma. Initial data from 11 patients showed an 82% objective response rate (ORR) to treatment, which is better than 70% ORR that the trial was configured to show.



The Phase 2 SCOPE trial was designed to determine if the ORR in patients with unresectable metastatic melanoma could be improved in combination with CPIs. The concept is that the vaccine induces new, or boosts existing, immune responses which are subsequently protected in the tumour environment by the CPIs. During the first stage of the SCOPE trial patients received SCIB1 via a needle-free device in combination with the most efficacious treatment currently available, namely the CPIs nivolumab and ipilimumab. The first milestone in the SCOPE trial was to achieve responses in more than 8 out of 15 patients which would suggest that SCIB1 in combination with doublet CPI therapy might meaningfully improve current outcomes for these patients. 16 stage IV metastatic patients have received this combination. To date, 11 of these study patients have reached 13 weeks and been evaluated at radiological imaging and nine have already shown an objective response, equating to an ORR of 82% with no increase in toxicity. At this time point the reduction in tumour volume was 31%-94%. Four patients reaching the 25 weeks imaging evaluation and two reaching the 37 weeks evaluation have shown a 69%-94% and a 87%-94% reduction in total tumour burden, respectively. This compares to an ORR of 50% reported in patients just receiving this doublet CPI therapy in the real world setting with a progression free survival time of 11.5 months.



Prof Poulam Patel, Chief Investigator, added: "These results, if confirmed in a larger cohort, will be a significant improvement on what patients can expect from available treatment today. We look forward to continuing the second stage of the study and reporting further data in due course."



Prof Lindy Durrant, Chief Executive Officer of Scancell, commented: "We are excited by these highly impressive results for SCIB1 combined with the doublet CPI therapy. We thought results from the Phase 1/2 trial evaluating SCIB1 as a monotherapy were positive but results from this combination are even more meaningful. Previous studies indicated that a response rate of 50% was the best that could be achieved in the real world setting for patients with unresectable metastatic melanoma, as no other combination had improved on the response rates for doublet CPI alone. Confirmation of this data in a larger cohort could make a significant impact on melanoma patient survival, especially as melanoma is now one of the most common cancers in young women."



The SCOPE trial has now successfully transitioned into the second stage, which will recruit a further 27 patients (for a total of 43). The aim is to achieve at least 18 further responses (i.e., 27 responses in total) which would statistically demonstrate that SCIB1, in combination with doublet therapy, exceeds currently achievable ORRs. Recruitment is expected to be complete by the end of 2023 with data available in H1 2024. Based upon the first 11 patients there is a greater than 90% probability that the second phase will also be successful.



An amendment to the current trial protocol, to include a new parallel cohort with the double CPIs with iSCIB1+, has been submitted to the Medicines and Healthcare products Regulatory Agency (MHRA). iSCIB1+ has a number of additional competitive advantages to SCIB1, including potentially increased potency due to modifications to the product using Scancell's propriety AvidiMab® platform, and an extended patent life. iSCIB1+ is also able to be used by a broader patient population because it incorporates more melanoma-specific epitopes. It is anticipated that data from this cohort will read out in the first half of 2024.



If validated in the second stage of the SCOPE trial this will provide confidence to initiate a randomised phase 2/3 adapted registration programme in patients with unresectable melanoma which represents a potential $1.5 billion per annum market. The Phase 2 part of the adapted trial should take 18 months and will likely generate significant partner interest.



In addition to SCIB1, Scancell expects significant results from its other programmes in 2024 including top-line Modi-1 CPI combination data and attractive out-licensing opportunities from the GlyMab® and AvidiMab® platforms."""

[inanaco] 19/9/2023 07:09

we know as lindy has stated PD-1 has little effect on moditope ...

so why would scancell consider it .......

Modi1 has induced a response .....

thus we have effector cytokines produced to attract other immune effector cells

its these cells that fall under the knife of PD-1 ....

and moditope is partially inhibited

the cancer seeing those cytokines puts up a defence using PD-1

trying to turn off the t cells

partially successful against moditope but 100% against other effector cells

this is why "stable" with ovarian is so valuable

because the cancer is up regulating PD-1


think about it ...

add pd-1 .

you get moditope plus normal immune effector cells


synergy

[inanaco] 19/9/2023 07:01

now you may say why did we not treat tilly with a pd-1 as well .......

that would completely mess up the trial statistics .........

rendering the pfs the ORR and OS rate impossible to measure from the mono therapy arms

[inanaco] 19/9/2023 06:46

its all about maths sadly not the kind that gives the wrong answer 2 + 2 as developed by The Kept Mans delusion

we know a majority have responded to SCIB1 ....... N15

target is 9

majority is min 51 %

so 8

9 and over is commercial, the higher the number the higher the confidence attributed

also the depth of the response ..... Partial, complete or PFS progression free survival which you can drill down to as time moves on

this also applies to moditope but at a higher reward because the patients are not treatable as they have failed standard of care in the mono setting

and in ovarian the checkpoints have also failed to generate meaning full data

so 44% control rate from modi1 becomes significant as that fits into PFS

so our Tilly didn't fail the trial because it falls into PFS of approx 8 months

so all these states have value ............

for now we need a response rate of 9 or above .... the higher the number the less risk of a fluke ...if that is coupled with a higher efficacy then you have synergy so for instance more Partial responders etc

[801710245] 18/9/2023 23:34

Suddenly, the share price is a talking point.

...and yet, if you read the posts before/over the weekend, "The share price is irrelevant".

[knowlesi] 18/9/2023 23:06

Incredible - I see the share price returning to June 2023 levels is triggering investors to loose their minds that a big deal RNS is immennent. Scancell have never announced a big deal, ever - so that would be a turn up for the books. I see LSE is full of optimism and GF123, our resident captain of industry is back posting that all is well. Couple of points to flag on this charlatan in case any one thinks he is the sort of bloke you may trust: 1) He didn't pay a 100 bet to charity on loosing a bet to me. Strange considering his (claimed) wealth. 2) He threatened to expose my identity publically (annoyed that my public predictions were right ever time) - strange considering I attended an AGM and 2 investor events as myself. By the way he still got my identity wrong - some bloke with the same name. 3) He promised he would attend the last AGM - he didn't as he was too busy. This is a guy who owns circa 1% of the company (or so he claims). Captain pugwash is picking up his car tomorrow - poor bloke must have lost at best 200k on scancell, at best!!!!!

[nigelpm] 18/9/2023 22:06

Bermuda - I think MT meant 15-20m shares i.e. between £1.5m and £3m.

[marcusl2] 18/9/2023 21:38

AvidiMab technology has been applied to the anti-glycan mAbs to improve their
ability to directly kill tumour cells, without mediation by other elements of the
immune system. The AvidiMab platform has also been used to increase the
potency of the T cell response in the COVIDITY vaccine programme and, in turn,
to the SCIB oncology programmes (named iSCIB). With the ImmunoBody vaccines
AvidiMab improves the breadth of response, increases potency, provides better
long-term protection and immunological memory, and extends patent lifetimes.
These programmes, particularly COVIDITY given its high profile, should produce
robust evidence of the clinical value AvidiMab provides and lead to its being
employed in external programmes.

[bermudashorts] 18/9/2023 21:31

MarkingTime

Why would any fund wanting to invest £15m to £20m in an AIM bio buy in dribs and drabs on the open market, particularly when that bio has just scaled back its planned clinical trials to conserve cash and would presumably welcome some equity funding with open arms?